Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EXECUTIVE CHANGES: Long-serving Hansard and Northbridge CEOs retire

Fri, 12th Mar 2021 15:39

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Friday and not separately reported by Alliance News:

----------

Hansard Global PLC - Isle of Man-based specialist long-term savings provider - Gordon Marr to retire by the end of 2021 after 8 years as chief executive officer and 30 years with the company. Has initiated a search for a new CEO. "I have decided to announce my retirement plans now, providing ample time to identify a successor and ensure a smooth transition," Marr says. "I am committed to leading the company in the meantime, as we remain resolutely focused on delivering a solid performance in 2021, while positioning the company for further success in the future."

----------

Northbridge Industrial Services PLC - Burton on Trent, England-based firm that hires and sells specialist industrial equipment - CEO & Founder Eric Hook will step down from the board on March 31 after 15 years in post but remain as an advisor and significant shareholder. Chair Peter Harris will become executive chair with the directors of Northbridge's two divisions - Chris Caldwell of Crestchic and Ian Gardner of Tasman - reporting to him. Additionally Caldwell will be promoted to the board. Non-Executive Director Stephen Yapp is promoted to senior independent director, while Ash Mehta will step down as non-executive director.

----------

ReNeuron Group PLC - Bridgend, Wales-headquartered cell-based therapeutics - Chief Financial Officer Michael Hung resigns on Thursday "in order to pursue other projects", having joined the board in early 2001. Hung will remain until the end of May, and ReNeuron have started a search for his replacement.

----------

Anpario PLC - Nottinghamshire-based sustainable animal feed additives - Hires Ian Hamilton as non-executive director, starting April 1. Hamilton was in the founding management team of poultry breeding business Aviagen. He currently is non-executive chair of Horizon Proteins Ltd, which provides sustainable proteins for aquaculture recycled from the whiskey-making process, and of Biotangents Ltd, a veterinary diagnostics business.

----------

Gooch & Housego PLC - Ilminster, Somerset-based maker of optical components - Hires Jim Haynes as non-executive director, starting Friday. Haynes was executive vice president of operations at US optical components firm Oclaro Inc, which was bought by Lumentum Holdings Inc at the end of 2018.

----------

Universe Group PLC - Southampton, Hampshire-based retail management, payment and loyalty systems - Hires Neil Radley as CEO, joining Universe Group on May 1. Most recently, Radley led Jaja Finance Ltd, a fintech lending firm. He also has worked at Barclaycard, HBOS PLC and Bank One International. Radley replaces Jeremy Lewis, who the company last month said will leave on April 30 "to pursue other opportunities outside of the public markets", after seven years with Universe.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
23 Oct 2019 09:32

ReNeuron Shares Jump As Lead Cell Line Shows Further Potential

ReNeuron Shares Jump As Lead Cell Line Shows Further Potential

Read more
2 Oct 2019 15:15

ReNeuron Reports Mixed Results For Retinitis Pigmentosa Trial

ReNeuron Reports Mixed Results For Retinitis Pigmentosa Trial

Read more
21 Aug 2019 11:49

ReNeuron boosts scientific advisory board with three appointments

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced the appointment of professor Robert MacLaren, Dr Sally Temple and Dr José-Alain Sahel to its scientific advisory board on Wednesday.

Read more
14 Aug 2019 15:35

ReNeuron's New Cardiff University Venture Gets Research Grant

(Alliance News) - ReNeuron Group PLC on Wednesday said a new venture with Cardiff University has secured a UK government grant to research and develop new treatments for hard-to-target disorders a

Read more
14 Aug 2019 11:16

ReNeuron enters grant-funded partnership with University of Cardiff

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group is partnering with the University of Cardiff under a new grant-funded collaboration utilising its exosome-based drug delivery technology platform, it announced on Wednesday.

Read more
16 Jul 2019 12:16

ReNeuron Secures Patents For Its Exosome Technology Platform

(Alliance News) - ReNeuron Group PLC on Tuesday said it has expanded its intellectual property estate via the grant of patents, covering its exosome technology platform.The cell-based said

Read more
11 Jul 2019 11:36

ReNeuron Annual Loss Narrows On Finance Income And Licence Fee

(Alliance News) - ReNeuron Group PLC on Thursday said its loss narrowed in its most recent financial year after it received an exclusivity fee and increased finance income.Shares in were at

Read more
14 Jun 2019 15:49

ReNeuron wins 'Breakthrough of the Year' at European Mediscience Awards

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group has won the 'Breakthrough of the Year' award at the 2019 European Mediscience Awards, it announced on Friday.

Read more
8 May 2019 11:19

ReNeuron Expects Annual Results In Line With Views After Progress

LONDON (Alliance News) - ReNeuron Group PLC on Wednesday said it expects its annual results to be in line with the board's expectations as it made progress on several clinical cell-based also

Read more
8 May 2019 08:53

ReNeuron advances blindness and stroke therapy candidates

(Sharecast News) - Therapeutics outfit ReNeuron continued to trade in line with expectations throughout its recently wrapped up trading year, advancing both its human retinal progenitor cell therapy candidate and its CTX cell therapy candidate.

Read more
26 Apr 2019 12:09

ReNeuron upbeat on early data from retinitis pigmentosa trials

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced updated positive preliminary data in its ongoing phase 1 and 2a clinical trial of its human retinal progenitor cell (hRPC) therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP), on Friday.

Read more
26 Apr 2019 09:58

ReNeuron Reports Positive Test Results For Blindness Treatment Therapy

LONDON (Alliance News) - ReNeuron Group PLC on Friday reported positive trial results for its human retinal progenitor cell therapy candidate for treating blindness-causing disease retinitis in up

Read more
11 Apr 2019 18:24

DIRECTOR DEALINGS: ReNeuron Chair And Other Board Members Buy Shares

LONDON (Alliance News) - ReNeuron Group PLC said a number of directors purchased shares on Thursday, including Non-Executive Chair John Berriman who bought 80,000 shares at 225 pence Thursday, in

Read more
9 Apr 2019 10:55

ReNeuron Signs Licence Deal For CTX, hRPC Cell Programmes In China

LONDON (Alliance News) - ReNeuron Group PLC on Tuesday said it has signed an exclusive licence agreement for the development, manufacture and commercialisation of its CTX and hRPC cell therapy in

Read more
4 Apr 2019 14:19

ReNeuron upbeat on progress in hRPC study

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group updated the market on progress with its ongoing phase 1 and 2 clinical trial in the US of its 'hRPC' cell therapy candidate in the blindness-causing disease retinitis pigmentosa (RP) on Thursday, confirming that the positive efficacy seen and previously announced had, to date, been sustained in the first patient cohort in the phase 2 part of the study.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.